Xcyte Therapies, Inc. And Invitrogen Corporation Announce Signing Of Asset Purchase Agreement

Published: Dec 15, 2005

SEATTLE & CARLSBAD, Calif.--(BUSINESS WIRE)--Dec. 15, 2005--Xcyte Therapies, Inc. (Xcyte) (Nasdaq:XCYT) (Nasdaq:XCYTP) and Invitrogen Corporation (Nasdaq:IVGN) today announced they have entered into a definitive agreement for Invitrogen to acquire Xcyte's T cell expansion technology, known as the "Xcellerate Process." The acquired assets will include intellectual property, the clinical data generated by Xcyte in the course of six clinical trials of its lead product, Xcellerated T Cells, as well as raw materials and equipment.

Back to news